This market asks whether the FDA will issue a formal approval letter by December 31, 2027 for V940 together with pembrolizumab specifically in resected high-risk melanoma. The treatment has encouraging Phase 2b evidence, including a reported 49% reduction in recurrence or death versus pembrolizumab alone, and it has FDA Breakthrough Therapy Designation. However, the pivotal Phase 3 INTerpath-001 study is listed as active but not recruiting, with a primary completion date in October 2029, and the FDA reportedly closed the accelerated-approval path. No FDA filing, accepted application, review deadline, approval, CRL, or denial for this indication was found, so the positive efficacy signal is balanced by substantial timing and regulatory uncertainty.
